title: Alemtuzumab for multiple sclerosis: who and when to treat?
authors.affiliation: Department of Neurology, University Hospital Basel, CH 4031, Basel, Switzerland.
authors.forename: Till
authors.initials: T
authors.lastname: Sprenger
authors.forename: Ludwig
authors.initials: L
authors.lastname: Kappos
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D010455:Peptides; D000074323:Alemtuzumab; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a